Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

1963
2025

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1982 3
1984 1
1985 3
1986 4
1987 1
1988 5
1989 9
1990 5
1991 8
1992 5
1993 6
1994 9
1995 5
1996 12
1997 10
1998 11
1999 5
2000 6
2001 12
2002 15
2003 17
2004 17
2005 21
2006 24
2007 25
2008 38
2009 22
2010 26
2011 19
2012 13
2013 26
2014 21
2015 20
2016 18
2017 20
2018 18
2019 15
2020 25
2021 22
2022 25
2023 26
2024 17
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

555 results

Results by year

Filters applied: . Clear all
Page 1
Systemic sclerosis-associated interstitial lung disease.
Perelas A, Silver RM, Arrossi AV, Highland KB. Perelas A, et al. Lancet Respir Med. 2020 Mar;8(3):304-320. doi: 10.1016/S2213-2600(19)30480-1. Epub 2020 Feb 27. Lancet Respir Med. 2020. PMID: 32113575 Review.
Currently, interstitial lung disease is the most common cause of death among patients with systemic sclerosis, with a prevalence of up to 30% and a 10-year mortality of up to 40%. Interstitial lung disease is more common among African Americans and in people with th …
Currently, interstitial lung disease is the most common cause of death among patients with systemic sclerosis, with a prevalen …
Systemic sclerosis in adults. Part I: Clinical features and pathogenesis.
Jerjen R, Nikpour M, Krieg T, Denton CP, Saracino AM. Jerjen R, et al. J Am Acad Dermatol. 2022 Nov;87(5):937-954. doi: 10.1016/j.jaad.2021.10.065. Epub 2022 Feb 4. J Am Acad Dermatol. 2022. PMID: 35131402 Review.
Systemic sclerosis (SSc), also referred to as systemic scleroderma or scleroderma, is a rare, complex immune-mediated connective tissue disease characterized by progressive skin fibrosis and other clinically heterogenous features. ...Recent deve
Systemic sclerosis (SSc), also referred to as systemic scleroderma or scleroderma, is a rare, complex imm
State-of-the-art evidence in the treatment of systemic sclerosis.
Pope JE, Denton CP, Johnson SR, Fernandez-Codina A, Hudson M, Nevskaya T. Pope JE, et al. Nat Rev Rheumatol. 2023 Apr;19(4):212-226. doi: 10.1038/s41584-023-00909-5. Epub 2023 Feb 27. Nat Rev Rheumatol. 2023. PMID: 36849541 Free PMC article. Review.
Systemic sclerosis (SSc) is a rare autoimmune connective tissue disease with multi-organ involvement, fibrosis and vasculopathy. Treatment in SSc, including early diffuse cutaneous SSc (dcSSc) and the use of organ-specific therapies, has improved, as evident
Systemic sclerosis (SSc) is a rare autoimmune connective tissue disease with multi-organ involvement, fibrosis and vasculopath
Current advances in the treatment of systemic sclerosis.
Bukiri H, Volkmann ER. Bukiri H, et al. Curr Opin Pharmacol. 2022 Jun;64:102211. doi: 10.1016/j.coph.2022.102211. Epub 2022 Apr 18. Curr Opin Pharmacol. 2022. PMID: 35447517 Free PMC article. Review.
Systemic sclerosis (SSc) is a rare, systemic autoimmune disease of unknown etiology. Among the systemic rheumatic diseases, SSc carries the highest mortality, in part due to the historical lack of disease modifying therapies. ...Although SSc affects va
Systemic sclerosis (SSc) is a rare, systemic autoimmune disease of unknown etiology. Among the systemic rheumati
Eosinophilic Fasciitis: Current and Remaining Challenges.
Mazilu D, Boltașiu Tătaru LA, Mardale DA, Bijă MS, Ismail S, Zanfir V, Negoi F, Balanescu AR. Mazilu D, et al. Int J Mol Sci. 2023 Jan 19;24(3):1982. doi: 10.3390/ijms24031982. Int J Mol Sci. 2023. PMID: 36768300 Free PMC article. Review.
Eosinophilic fasciitis (EF), defined as diffuse fasciitis with eosinophilia by Shulman in 1974, is a disease with unknown etiology and whose pathogenesis is still being researched. ...
Eosinophilic fasciitis (EF), defined as diffuse fasciitis with eosinophilia by Shulman in 1974, is a disease with unknown etiology an …
Systemic sclerosis sine scleroderma.
Kucharz EJ, Kopeć-Mędrek M. Kucharz EJ, et al. Adv Clin Exp Med. 2017 Aug;26(5):875-880. doi: 10.17219/acem/64334. Adv Clin Exp Med. 2017. PMID: 29068586 Free article. Review.
Systemic sclerosis is a rare generalized disease with scleroderma, i.e. skin thickening as one of the most common symptoms. The disease has 2 main subsets, diffuse and limited forms. The subset known as systemic sclerosis sine sclerode
Systemic sclerosis is a rare generalized disease with scleroderma, i.e. skin thickening as one of the most common sympt
Scleroderma epidemiology update.
Calderon LM, Pope JE. Calderon LM, et al. Curr Opin Rheumatol. 2021 Mar 1;33(2):122-127. doi: 10.1097/BOR.0000000000000785. Curr Opin Rheumatol. 2021. PMID: 33481429 Review.
PURPOSE OF REVIEW: Systemic sclerosis (scleroderma, SSc) is a rare multisystem autoimmune disease characterized by autoantibodies, vasculopathy, and fibrosis of the skin and internal organs. This review aims to provide an overview and summary of the recent ep …
PURPOSE OF REVIEW: Systemic sclerosis (scleroderma, SSc) is a rare multisystem autoimmune disease characterized by auto …
Systemic sclerosis: one year in review 2024.
Lepri G, Di Battista M, Codullo V, Bonomi F, Sulis A, Guiducci S, Della Rossa A. Lepri G, et al. Clin Exp Rheumatol. 2024 Aug;42(8):1517-1528. doi: 10.55563/clinexprheumatol/is29he. Epub 2024 Jul 26. Clin Exp Rheumatol. 2024. PMID: 39058484 Free article. Review.
Systemic sclerosis (SSc) is a rare and chronic connective tissue disease of unknown aetiology and characterised by three main pathogenetic events represented by endothelial damage, inflammation with activation of the immune system leading to production of specific a
Systemic sclerosis (SSc) is a rare and chronic connective tissue disease of unknown aetiology and characterised by three main
Treatment for systemic sclerosis-associated interstitial lung disease.
Roofeh D, Lescoat A, Khanna D. Roofeh D, et al. Curr Opin Rheumatol. 2021 May 1;33(3):240-248. doi: 10.1097/BOR.0000000000000795. Curr Opin Rheumatol. 2021. PMID: 33741803 Free PMC article. Review.
PURPOSE OF REVIEW: This review provides an overview of the current treatments for systemic sclerosis-interstitial lung disease (SSc-ILD) and proposes a conceptual framework for disease management with case scenarios. ...A high-quality randomized controlled trial dem …
PURPOSE OF REVIEW: This review provides an overview of the current treatments for systemic sclerosis-interstitial lung disease …
Scleromyositis: A distinct novel entity within the systemic sclerosis and autoimmune myositis spectrum. Implications for care and pathogenesis.
Giannini M, Ellezam B, Leclair V, Lefebvre F, Troyanov Y, Hudson M, Senécal JL, Geny B, Landon-Cardinal O, Meyer A. Giannini M, et al. Front Immunol. 2023 Jan 26;13:974078. doi: 10.3389/fimmu.2022.974078. eCollection 2022. Front Immunol. 2023. PMID: 36776390 Free PMC article. Review.
Systemic sclerosis and autoimmune myositis are both associated with decreased quality of life and increased mortality. Their prognosis and management largely depend on the disease subgroups. Indeed, systemic sclerosis is a heterogeneous disease, the tw
Systemic sclerosis and autoimmune myositis are both associated with decreased quality of life and increased mortality. Their p
555 results